The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a significant substantial reduction in body mass and enhance metabolic healt